Introduction
============

Tuberculosis (TB) is the ninth leading cause of death worldwide and the leading cause from a single infectious agent that is ranking above HIV/AIDS. The disproportionate burden of HIV and TB infection and disease in Africa at the start of the new millennium continues unabated. In 2016, of all estimated 10.4 million new cases of (25% in Africa) TB that resulted in 1.7 million (44% in Africa) deaths worldwide, Africa though, home to only 13% of the world's population have been living in Africa. Africa bears 30% of HIV prevalence among TB patients or its co-infection as compared to 1.3% by the Eastern Mediterranean region. HIV prevalence in TB patients or co-infection was low in Eastern Mediterranean region (1.3%), nevertheless, it was 30% in Africa.[@b1-hiv-10-225]

Furthermore, Africa bears 75% of about 1.03 million of TB/HIV co-infection cases that occur each year globally. Furthermore, in Africa, TB is often observed first in HIV-infected patients, and it is the leading cause of death among them.[@b1-hiv-10-225] In addition, the UNAIDS global report in 2016 showed that sub-Saharan Africa (SSA) takes the lead by contributing the highest burden of HIV: 70% (25.5 million) of 36.7 million people living with HIV, 64% of 1.8 million newly infected, and 73% of 1.0 million deaths.[@b2-hiv-10-225]

Extrapulmonary TB (EPTB) is the TB of organs other than the lungs, eg, pleura, lymph nodes, abdomen, genitourinary tract, skin, joints, bones, and meningeal.[@b3-hiv-10-225],[@b4-hiv-10-225] A majority of individuals after exposure control the spread of bacillia in pulmonary site, but in others bacilli disseminate through lymphatic or hematogenous system and subsequently affect single or multiple extrapulmonary sites.[@b5-hiv-10-225] The prevalence of EPTB among notified TB cases in African region in 2017 was 16%, which is the second highest next to Eastern Mediterranean region (24%), which is more than global prevalence of EPTB (15%). The lowest prevalence was reported from Western Pacific region (8%).[@b1-hiv-10-225]

To mitigate the burden of EPTB/HIV co-infection, the WHO took the initiative. In 2007, it published guidelines on how to diagnose EPTB among HIV-positive people which were based on one culture-positive specimen or histological or strong clinical evidence consistent with active EPTB, followed by a decision by a clinician to treat with a full course of anti-TB treatments.[@b6-hiv-10-225] In addition, the WHO published an up-to-date policy on collaborative TB/HIV activities in 2012.[@b7-hiv-10-225] This policy emphasized the importance of surveillance of HIV among TB patients and vice versa in all countries. Furthermore, in 2013, the WHO updated the policy on the diagnosis of TB using GeneXpert *Mycobacterium tuberculosis/rifampicin* as an initial diagnostic test at point of care. It could replace microscopy and be used for diagnosis of all presumptive pulmonary TB (PTB) patients, pediatrics patients, TB/HIV co-infected patients, and selected specimen of the diagnosis of EPTB patients.[@b8-hiv-10-225],[@b9-hiv-10-225]

A wide range of estimates for the prevalence of EPTB among people living with HIV/AIDS (PLWHA) have been reported from different SSA countries. For instance, in Ethiopia, more than half, 54.7% co-infection among HIV/AIDS individuals, had EPTB.[@b10-hiv-10-225] In Cameroon and Ghana, HIV co-infection with EPTB was 37.1% and 45.2%, respectively.[@b11-hiv-10-225],[@b12-hiv-10-225] However, an estimate reported on the prevalence of EPTB among PLWHA was inconsistent and unclear.

Therefore, for the dual burden of TB/HIV affecting the Africa, we aimed to summarize and synthesize the prevalence of EPTB among HIV-positive individuals in SSA. This is important for public health policy and planning and development of clinical services that address the needs of EPTB and HIV/AIDS patients.

Methods
=======

Study participants
------------------

The study participants included as a sample in reviewed studies could be males and females; all age groups; the time of screening or diagnosing EPTB among HIV had been at the same time (both tested at a time) or after the HIV status is known. The time of reviewed studies performed could be either when HIV/AIDS patients have been in pre-antiretroviral therapy or taking antiretroviral therapy.

Outcome
-------

This review considered studies that include the prevalence estimate of EPTB among PLWHA.

Eligibility criteria
--------------------

For our review, we included the studies that have been done on PLWHA and reported the proportion of co infection for EPTB and HIV. Included studies were observational study design, which includes cohort (prospective or retrospective), cross-sectional or medical review. Studies that were written only in English, health facilities that could be hospitals, health centers or similar that belong to governmental or nongovernmental, or private, and published between January 1, 1990, and November 30, 2017, were included. The screening or investigations were included irrespective of diagnostic methods. Abstracts without full texts, articles without journal name and/or authors, conference proceeding or presentation, studies with total population of less than 50 people, study with incidence, qualitative study, review, case study, TB/HIV co-infection or PTB/HIV only co-infection, and book chapters were excluded from the final analysis.

Search strategy
---------------

A three-stage search strategy was used to identify all relevant published literature. First, an initial search of PubMed database and Google Scholar was made. Second, searching the reference lists or bibliographies of all identified articles was checked manually for articles of interest, and finally gray literature was sought from institutions and government websites. Available electronic journal articles were searched through HINARI. We also searched relevant reference lists and relevant journals manually. The dates of publication covered were January 1, 1990, to November 30, 2017. The search engine used with modification was with initial keywords and Medical Subject Headings (MeSH) term for PubMed database: "Tuberculosis, lymph node" OR "tuberculosis, cardiovascular" OR "tuberculosis, central nervous system" OR "tuberculosis, cutaneous" OR "tuberculosis, endocrine" "tuberculosis, gastrointestinal" OR "tuberculosis, hepatic" OR "tuberculosis, ocular" OR "tuberculosis, oral" OR "tuberculosis, osteoarticular" OR "tuberculosis, pleural" OR "tuberculosis, splenic" OR "tuberculosis, urogenital" OR "tuberculosis" AND "HIV" OR "AIDS" OR "human immunodeficiency virus" OR "acquired immunodeficiency syndrome" OR "co-infection" OR "opportunistic infection" OR "opportunistic" OR "sub Saharan Africa".

Methods of EPTB screening or diagnosis among PLWHA
--------------------------------------------------

WHO or National TB Control Program diagnostic methods of the respective country were used; either combination or individual screening methods were used; either of the following methods were used: microbiologically determined sputum microscopy or sputum culture, PCR, GeneXpert, X-ray, broncho-alveolar lavage, histopathology, and ultrasound. Clinical signs and symptoms and response to treatment in combination with one of the abovementioned diagnostic methods were also used. In addition, methods of HIV screening or diagnosis as per WHO or national HIV screening or diagnosis protocol which mainly either rapid test or ELISA test or both were used.

Methodological quality assessment
---------------------------------

All articles selected for inclusion in the review were subjected to a rigorous, independent appraisal by the investigators prior to inclusion in the review using standardized critical appraisal instruments from the Joanna Briggs Institute (JBI).[@b13-hiv-10-225] Two reviewers independently appraised the studies. Disagreement was resolved by consensus between the two reviewers or through consultation with the third author, if required. The checklists were focused on setting, method of sampling techniques and sample size determination, screening/diagnostic method, and validity and reliability of measurements and data analysis. All relevant studies with optimum score were included and discussed with its limitations and risk of biases and how that might affect the results of this review.

Study selection
---------------

After studies were identified, we selected studies by passing through four steps primarily screening through titles and abstracts with over inclusion; second, full-text review for eligibility checkup was performed. Third, methodological critical appraisal was performed, and finally studies having optimum quality were included for systemic review and meta-analysis.

Data collection process: data item and extraction tools
-------------------------------------------------------

We used a standardized form of JBI for data item and extraction.[@b13-hiv-10-225] This data extraction form was used to extract the relevant information from appraised articles. A number of variables including study locations or country, years of publications, study periods, study designs, number of patients included in the study, and prevalence of EPTB/HIV co-infection were extracted from all studies included in the review. For this review, we used summary estimate rather than individual patient-level data.

Data analysis and statistical methods
-------------------------------------

Prevalence of EPTB was calculated as a number of EPTB cases per total number of PLWHA. The prevalence data were identified and abstracted or calculated from the given data from respective studies. In studies, when the standard error (SE) was not reported, we calculated it from the prevalence by using the following formula: SE = √P (1--P)/N and 95% CI = P±1.96 × SE, where P is the prevalence, N is the sample size or included PLWHA.

Meta-analysis was done by using Review Manager Software (version 5.3; the Cochrane Collaboration, 2014) and Compressive Meta-analysis Software (version 2.2). Heterogeneity of studies was assessed using Cochran's *Q* (reported as χ^2^, *P*-values, and degrees of freedom \[*df*\]) and *I*^2^ statistics, which described the percentage of total variation between studies that were due to inconsistency rather than chance.[@b14-hiv-10-225] Unlike *Q*, *I*^2^ is inherently dependent on the number of studies included in the review: its values of 25%, 50%, and 75% show low, moderate, and high degrees of heterogeneity, respectively. We also used inverse variance, random-effects model and proportion for the effect size estimate. Unlike fixed-effects model, random-effects model enabled us to see within and between study variations using Kendall's τ^2^.[@b15-hiv-10-225] Sensitivity analysis and subgroup analysis were also performed. Funnel plot was used to see the possibility of publication bias and statistical tests of Egger's regression analysis and Begg's rank correlation analysis.[@b16-hiv-10-225] We used forest plot to summarize the effect size. Finally, we used PRISMA standard for reporting.[@b17-hiv-10-225]

Results
=======

Study characteristics
---------------------

In our search, we found 341 records. After the removal of duplicates and initial screening of titles and abstracts, we identified 121 potential full-text articles for eligibility. After screening the full-text articles, we included 31 studies in the review with 28,659 HIV-positive people ([Figure 1](#f1-hiv-10-225){ref-type="fig"}).

Methodological quality assessment of included studies
-----------------------------------------------------

The methodological quality assessments of studies were assessed by using JBI critical appraisal. As per the standard, the study that had optimum quality that was above the mean for "yes" was included ([Table 2](#t2-hiv-10-225){ref-type="table"}).

Meta-analysis
-------------

Our primary meta-analyses aimed to summarize the prevalence of EPTB among PLWHA.

On meta-analysis, data of 28,659 PLWHA as a sample were used to estimate the proportion of EPTB. The summary effect or pooled proportional estimate of meta-analysis of EPTB among PLWHA was found to be 20% (95% CI: 17, 22; heterogeneity: τ^2^=0; χ^2^=509.09, *df*=30, *P*\<0.00001; *I*^2^=94%; [Figure 2](#f2-hiv-10-225){ref-type="fig"}).

Sensitivity analysis
--------------------

For the statistical fidelity, sensitivity analysis was performed using Compressive Meta-Analysis Software by removing one study while keeping the others in random-effects model, and by excluding one large study,[@b32-hiv-10-225] the prevalence estimate of EPTB among PLWHA was not changed, 20% (95% CI: 17, 23; heterogeneity: τ^2^=0.01; χ^2^=507.37, *df*=29, *P*\<0.00001; *I*^2^=94%; [Table 3](#t3-hiv-10-225){ref-type="table"}).

Subgroup analysis
-----------------

Subgroup analysis was done to find heterogeneity based on age, types of EPTB, study design, subregion of SSA, and countries having two or more studies and the time variation. For instance, by study population age group, inconsistency of the estimate was not removed, the EPTB among PLWHA did not vary by age group when we compared children \<15 years,[@b23-hiv-10-225],[@b28-hiv-10-225],[@b39-hiv-10-225] adults ≥15 years[@b11-hiv-10-225],[@b21-hiv-10-225],[@b46-hiv-10-225] or ≥18 years[@b25-hiv-10-225],[@b29-hiv-10-225],[@b33-hiv-10-225] and all age groups in remaining 21 studies ([Table 3](#t3-hiv-10-225){ref-type="table"}).

Effect of publication year on estimate
--------------------------------------

To determine the effect of year of publications on EPTB prevalence estimate among PLWHA, we performed meta-regression using Compressive Meta-analysis (CMA) Software. We observed that publication year increased by a year and the point estimate of EPTB prevalence among PLWHA increased with 0.4% at 95% CI (0.2, 0.6%), *P*=0.00067 ([Figure 3](#f3-hiv-10-225){ref-type="fig"}).

Publication bias
----------------

We assessed publication bias using CMA Software through funnel plot and regression tests with random-effects model for included studies ([Figure 4](#f4-hiv-10-225){ref-type="fig"}). There was no publication bias. In addition, we performed statistical test, and no evidence of publication bias was observed (*P*=0.44 for Egger's regression analysis; *P*=0.11 for Begg's rank correlation analysis).

Discussion
==========

In our systematic review and meta-analysis of EPTB among PLWHA, we selected 31 studies with 28,659 HIV/AIDS people. Our main findings showed that there was a high and diverse prevalence of EPTB among PLWHA in SSA which ranged from 6.4% (95% CI: 3.8, 9.0) in Nigeria[@b29-hiv-10-225] to 36.8% (95% CI: 28.6, 45.0) in Ethiopia.[@b19-hiv-10-225] The overall pooled estimate prevalence of EPTB among PLWHA was 20% (95% CI: 17, 22; heterogeneity: τ^2^=0; χ^2^=509.09, *df*=30, *P*\<0.00001; *I*^2^=94%).

This is high when we compared with the prevalence estimate of EPTB among notified TB cases in Africa. According to the WHO report of 2017, the prevalence of EPTB in Africa and world was 16% and 15%, respectively, among notified TB cases in 2016.[@b1-hiv-10-225] From the WHO report of 2017, we observed the prevalence of EPTB among notified TB cases for respective sub-Saharan countries, when we compared SSA by the geographical area, the eastern SSA was the lead, followed by Southern SSA, and the western was the least. One-third of the studies (ten of 31 studies) were conducted in Ethiopia, with highest prevalence of EPTB (32%) from SSA in notified TB cases, followed by Malawi 26%, Tanzania 21%, Zambia 18%, Burkina Faso, Kenya and Cameroon each 17%, South Africa 10%, Uganda 8%, and Nigeria 5%.[@b1-hiv-10-225]

However, the pooled prevalence of EPTB among PLWHA in subregions of SSA showed a slight difference with highest from southern SSA, 21% (95% CI: 15, 26); followed by eastern SSA, 20% (95% CI: 16, 23), and finally, western SSA, 19% (95% CI: 13, 24). This might be explained that the prevalence of HIV in population was high for the countries with evidence that included in the synthesis. That is, in 2016, SSA had the highest HIV/AIDS burden by sharing 70% (25.5 million) of 36.7 million people living with HIV, 64% of 1.8 million newly infected, and 73% of 1.0 million deaths worldwide.[@b2-hiv-10-225] The HIV/AIDS burden varies among subregions of SSA countries as eastern and southern Africa is the region hardest hit by HIV/AIDS with lion share, 53% of 36.7 million PLWHA and western and central Africa shares 17%, making 70% of PLWHA in SSA.[@b2-hiv-10-225]

In SSA, the pooled estimate of prevalence of EPTB among PLWHA by countries having two or more studies in subgroup analysis showed higher when compared with estimated prevalence of EPTB among notified TB cases for Africa, 16%. For instance, in Cameroon from western Africa with three studies, the pooled prevalence was 25% (95% CI: 12, 37), which was more than national estimate 17%, in Ethiopia from eastern with 10 studies was 23% (95% CI: 17, 29) that was less than national estimate of 32%, and South Africa was 17% (95% CI: 14, 20) more than national estimate 10%,[@b1-hiv-10-225] but comparable with study done in respective countries.

Although the clinical presentations of TB among PLWHA vary by stage of HIV-positive individuals, TB is the common disease among them.[@b48-hiv-10-225] At an early stage of HIV infection, the ratio of PTB to EPTB is 80:20 and at late stage is 50:50.[@b49-hiv-10-225] In SSA, TB is often the first manifestation of HIV infection, and it is the leading cause of death among HIV-infected individuals.[@b50-hiv-10-225] Similarly, HIV infection is one of the most important risk factors associated with an increased risk of latent TB infection progressing to active TB disease. While only 10% of immunocompetent individuals infected with *M. tuberculosis* go on to develop active disease in their lifetime; 50% of those coinfected with HIV develop active TB.[@b51-hiv-10-225]

To reduce the burden of TB, the WHO's policy on collaborative TB/HIV activities recommends a combination of measures among HIV-infected individuals. These measures include intensified case finding, isoniazid preventive therapy, and infection control and antiretroviral therapy.[@b7-hiv-10-225]

Although good progress was made in countries of SSA for intensified TB case findings among HIV-positive individuals or vice versa, still more intensified case finding of TB among PLWHA shall be performed. More over, if TB screened among PLWHA, the documentation was low as 18% in Africa, thus, documentation needs more focus in Africa.[@b1-hiv-10-225] In addition, the SSA that had reviewed studies had not fulfilled the three 90th objectives, which is to indicate that, the 1st 90 means 90% of people who are living with HIV, know their HIV status(positive or negative), the 2nd 90 means 90% of people living with HIV are on ART treatment, and the 3rd 90 means among people using ART, 90% of their virus is suppressed.[@b2-hiv-10-225]

These findings are potentially important from a public health perspective since it suggests that more attention should be paid to screen EPTB among PLWHA, especially in countries with high EPTB in population of SSA (eg, Ethiopia and Malawi) and high HIV prevalence in population (eg, southern African countries).

Our sensitivity analyses showed that our overall results had no difference when we excluded one study with largest sample size.[@b32-hiv-10-225] The heterogeneity was substantial (*I*^2^=94%), and we performed subgroup analysis by age group, types of EPTB, study design, time period, subregion, and countries having two or more studies and observed reduced or zero heterogeneity ([Table 3](#t3-hiv-10-225){ref-type="table"}). Thus, we explored and investigated the sources of inconsistence and finally performed the pooled estimate. We determined the effect of publication year on effect estimate that also one of the sources of heterogeneity. We expected the clinical variation as EPTB could be varied based on the organ involved, and in the way that the setting at which laboratory investigation performed, by whom and by how many people performed and interpreted. In reviewed studies, there was study design variations. Some studies we reviewed were performed with retrospective review of medical records, this results in underestimating the prevalence of EPTB among PLWHA. Others could be conducted with cross-sectional design in which comes the difficulty to judge which comes first.[@b52-hiv-10-225] Similarly, at the analysis stage, appropriate analysis was not conducted in some studies that is why we excluded some studies when the prevalence of EPTB was not calculated, or not clear, and/or no data.

Overall, the bias that could possibly occur in some of the individual studies included in our review was selection bias that resulted from primary exposure or outcome measurement as the diagnosis of EPTB is challenging.[@b6-hiv-10-225] Especially, in HIV-positive individuals, TB is atypical, and some facilities where the studies conducted were at health centers or similar. In these facilities, the required material or profession might not present, and in some studies the HIV statuses of some EPTB patients were unknown.

Second, selection bias could occur at design stage, in which a majority of evidence suggested that 19 out of 31 studies were retrospective in nature. In this case, authors were endorsed to underway studies with entry criteria majorly including those records that had complete data and excluded incomplete that could lead to nonresponse or missed variables or cases even without indicating the proportion of incomplete records.[@b53-hiv-10-225] Finally, the information bias particularly during data collection time could be committed in some studies included in the review as mentioned earlier, because more than half of the studies involved data abstraction from article-based register without piloting or standardizing data abstraction checklists in addition to poor data handling practice in low-income developing countries.[@b54-hiv-10-225] Thus, in both cases, the prevalence of EPTB among PLWHA, we found in this review, could have been underestimated. For future study, we recommend that further details on exposures and outcome measurement, samples and sampling techniques, and analysis are required.

However, our study has derived its strengths from its capability of having estimating EPTB among PLWHA in double burdened and leading continent, Africa, although not without limitation. As there were diverse and overlapping diagnostic techniques that had been performed in studies we reviewed, we could not perform the analysis of diagnosis that limited us to compare the prevalence of EPTB among PLWHA by diagnostic techniques. In addition, we reviewed articles written and/or published only in English; data published in other languages were not obtained. We therefore recommend collaboration of researchers from different language backgrounds to do a more exhaustive research in the future.

Conclusion
==========

We can conclude from our analyses that the prevalence of EPTB among PLWHA was high. It is necessary to give emphasis for EPTB rather than assuming as a rare event and focusing only on PTB, specifically, when screening TB among PLWHA, widening the spectrum of screening to include all common EPTB types in countries with high EPTB and/or HIV prevalence in the population.
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![Forest plot including all available relevant studies on EPTB among PLWHA in SSA, 2017.\
**Abbreviations:** *df*, degrees of freedom; EPTB, extrapulmonary tuberculosis; PLWHA, people living with HIV/AIDS; SE, standard error; SSA, sub-Saharan Africa.](hiv-10-225Fig2){#f2-hiv-10-225}

![Scatter plot showing the effect of publication year on point estimate of prevalence of EPTB among PLWHA, SSA, 2017.\
**Abbreviations:** EPTB, extrapulmonary tuberculosis; PLWHA, people living with HIV/AIDS; SSA, sub-Saharan Africa.](hiv-10-225Fig3){#f3-hiv-10-225}

![Funnel plot for SE by point estimate (**A**) for included studies (**B**) and input studies that shown similar pooled estimate.\
**Abbreviation:** SE, standard error.](hiv-10-225Fig4){#f4-hiv-10-225}

###### 

Characteristics of the studies included in the systemic review in SSA, 2017

  Study                                       Country        Population characteristics                                                   Setting                                          EPTB investigation                                                                                   Study types                                           Date                                      Sample size or total included (HIV/AIDS)   Event
  ------------------------------------------- -------------- ---------------------------------------------------------------------------- ------------------------------------------------ ---------------------------------------------------------------------------------------------------- ----------------------------------------------------- ----------------------------------------- ------------------------------------------ -------
  Ade et al[@b43-hiv-10-225]                  Benin          All EPTB and new PTB patients with or without HIV and all age groups         Hospital                                         As per national program                                                                              Retrospective cohort                                  January to December 2011                  521                                        72
  Adejumo et al[@b30-hiv-10-225]              Nigeria        All TB patients with or without HIV and all age groups                       UBTH                                             Diagnosed as per Nigerian national program                                                           Retrospective review of treatment cards of patients   January 1, 2014, to December 31, 2014     72                                         10
  Affusim et al[@b29-hiv-10-225]              Nigeria        All HIV-positive TB patients, \>18 years                                     Teaching hospital                                As per national program                                                                              Cross-sectional                                       January to April 2007                     330                                        21
  Agbor et al[@b11-hiv-10-225]                Cameroon       All HIV/TB patients and inpatients, aged ≥15 years                           Hospital                                         As per national program                                                                              Cross-sectional                                       January 1, 2006, to June 30, 2013         335                                        119
  Alemie and Gebreselassie[@b18-hiv-10-225]   Ethiopia       All TB patients with or without HIV and all age groups                       Private health institution                       As per national program                                                                              Cross-sectional                                       In the year 2008/2009                     159                                        52
  Amare[@b19-hiv-10-225]                      Ethiopia       All children with TB aged \<15 years with or without HIV                     Private, public (primary, secondary, tertiary)   As per national TB program, for histological and radiological performance                            Retrospective cohort                                  January 1, 2012, to December 31, 2013     133                                        49
  Gebreegziabher et al[@b20-hiv-10-225]       Ethiopia       All TB patients with or without HIV and all age groups                       30 public health facilities                      As per national guidelines                                                                           Retrospective cohort study                            July 2007 and June 2012                   753                                        249
  Daniel et al[@b28-hiv-10-225]               Nigeria        All TB patients with or without HIV and all age groups                       Hospital                                         Culture and/or sputum smear, rapid test for HIV                                                      Retrospective review                                  January 1, 1991, to December 31, 1991     320                                        23
  Deribew et al[@b21-hiv-10-225]              Ethiopia       All adult ≥15-year TB patients with or without HIV                           Health centers                                   TB lymphadenitis was diagnosed based on clinical parameters and cytological examination              Cross-sectional                                       February 2009 to March 2009               81                                         10
  Esmael et al[@b22-hiv-10-225]               Ethiopia       All TB patients with or without HIV and all age groups                       Referral hospital                                AFB, chest radiographs, and for EPTB, pathological examination                                       Retrospective record review                           June 2008 to August 2013                  321                                        51
  Feldacker et al[@b45-hiv-10-225]            Malawi         All TB patients with or without HIV and all age groups                       TB/HIV integrated clinic                         Bacteriological or histopathological, opt-out HIV testing                                            Retrospective cohort                                  January 2008 to December 2010             5,561                                      1,117
  Gupta et al[@b32-hiv-10-225]                South Africa   All TB patients with or without HIV and all age groups                       Electronic TB registry                           ICD-10 classification used for EPTB, serology for HIV                                                Retrospective analysis                                2009                                      13,237                                     2,328
  Hailu et al[@b23-hiv-10-225]                Ethiopia       All children with TB aged \<15 years with or without HIV                     Health centers                                   Clinical history, chest X-ray, HIV testing, and histopathology                                       Retrospective study                                   January 2007 to December 2011             346                                        103
  Hoffmann et al[@b33-hiv-10-225]             South Africa   All adult \>18-year HIV-positive patients with liver TB                      Hospital                                         Clinical, laboratory, and radiography                                                                Retrospective study                                   2001--2009                                108                                        28
  Iliyasu and Babashani[@b31-hiv-10-225]      Nigeria        All HIV-positive patients with or without TB and all age groups              Teaching hospital                                Biopsy of tissue specimen, TB culture                                                                Retrospective review of charts                        January 2006 to December 2006             138                                        50
  Kamenju and Said[@b42-hiv-10-225]           Tanzania       All TB patients with or without HIV and all age groups                       Hospital                                         Smear, radiological tests, culture, biopsy, or a combination                                         Retrospective cross-sectional analyses                August 2008 to July 2009                  175                                        19
  Malkin et al[@b44-hiv-10-225]               Burkina Faso   All TB patients with or without HIV and all age groups                       TB center                                        Smear, radiological tests, culture, biopsy, or a combination                                         Cohort study                                          October 1988 to March 1992                112                                        22
  Mekonnen et al[@b24-hiv-10-225]             Ethiopia       All TB patients with or without HIV and all age groups                       Hospital and private clinic                      Clinical history with X-ray, ultrasound, and/or pathological techniques                              Retrospective study                                   January 2011 to December 2014             236                                        78
  Muttai et al[@b46-hiv-10-225]               Kenya          Adult ≥15-year TB patients diagnosed with HIV+                               Hospitals and health centers                     Not reported                                                                                         Retrospective chart review                            October 2006 to April 2008                846                                        145
  Namme et al[@b36-hiv-10-225]                Cameroon       All TB patients with or without HIV and all age groups                       Hospital                                         Smear, radiological tests, biopsy, or combination                                                    Cross-sectional                                       July 1, 2007, to June 30, 2011            438                                        108
  Njozing et al[@b37-hiv-10-225]              Cameroon       All TB patients with or without HIV and all age groups                       TB/HIV treatment center                          Clinical and/or radiological, biopsies and laboratory examination of aspirates from affected areas   Retrospective cohort                                  January 2006 to December 2007             1,473                                      206
  Ocama et al[@b38-hiv-10-225]                Uganda         All HIV-positive patients who suspected for liver disease                    Teaching hospital                                Stool analysis, ultrasound-guided liver biopsies                                                     Cross-sectional                                       May 2004 to March 2005                    77                                         7
  Nglazi et al[@b34-hiv-10-225]               South Africa   All TB patients with or without HIV aged ≥15 years                           Hospital                                         As per national guidelines                                                                           Retrospective cohort study                            October 2009 and June 2011                472                                        159
  Siddiqi et al[@b40-hiv-10-225]              Zambia         All HIV-positive patients with a CNS infection requiring a LP                Teaching hospital                                Receiving an LP microscopy, culture, Gram stain, and India ink testing on CSF                        Cross-sectional study                                 October 1, 2010 to May 31, 2012           331                                        48
  Skogmar et al[@b25-hiv-10-225]              Ethiopia       All TB patients with or without HIV and ≥18 years old                        Hospitals and health centers                     As per national program                                                                              Cross-sectional study                                 September 2010 to March 2012              307                                        91
  Tarekegne et al[@b26-hiv-10-225]            Ethiopia       All TB patients with or without HIV and all age groups                       Hospital                                         Pathological examination and/or clinical symptoms                                                    Retrospective study                                   September 2009 to August 2012             404                                        58
  Wobudeya et al[@b39-hiv-10-225]             Uganda         All children with TB aged \<15 years with or without HIV                     Five districts                                   As per national program and WHO                                                                      Retrospective cross-sectional study                   January 1, 2009, to December 31, 2010     168                                        24
  Yassin et al[@b27-hiv-10-225]               Ethiopia       All TB patients with or without HIV and all age groups                       District hospital                                Sputum microscopy, X-ray facilities                                                                  Prospective cohort                                    Not reported                              97                                         10
  Sinkala et al[@b41-hiv-10-225]              Zambia         All abdominal TB and HIV positive                                            University Teaching Hospital, Lusaka, Zambia     Culture *and/or* granulomatous on histopathological examination microscopy                           Cross-sectional study                                 September 2005 until May 2006             140                                        22
  Stolp et al[@b47-hiv-10-225]                Gabon          All TB with or without HIV and all age groups                                Albert Schweitzer Hospital, Lambarene, Gabon     Neelsen-stained sputum smear or on clinical grounds, HIV test                                        Retrospective study                                   January 2007 to December 2012             205                                        40
  van der Plas et al[@b35-hiv-10-225]         South Africa   Adults (\>18 years), hospitalized HIV and PTB or EPTB patients, not on ART   BCH, Cape town                                   Smear or culture, WHO guidelines, smear negative or EPTB in HIV-1-infected people                    Prospective observational cohort                      April 29, 2009, until February 28, 2011   112                                        20

**Abbreviations:** AFB, acid-fast bacilli; ART, antiretroviral therapy; BCH, Brooklyn Chest Hospital; CNS, central nervous system; CSF, cerebrospinal fluid; extrapulmonary TB; LP, lumbar puncture; PTB, pulmonary TB; SSA, sub-Saharan Africa; TB, tuberculosis; UBTH, University of Benin Teaching Hospital.

###### 

Critical appraisal results of studies of EPTB among PLWHA by using JBI prevalence critical appraisal checklist, SSA, 2017

  Study                                       Q1   Q2   Q3   Q4   Q5   Q6   Q7   Q8   Q9   Q10   Total       
  ------------------------------------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----- ------- --- ---
  Ade et al[@b43-hiv-10-225]                  Y    Y    Y    Y    Y    Y    Y    Y    N    Y     9       1   0
  Adejumo et al[@b30-hiv-10-225]              N    N    U    Y    Y    Y    Y    Y    N    N     5       4   1
  Affusim et al[@b29-hiv-10-225]              Y    Y    Y    Y    Y    Y    Y    Y    Y    U     9       0   1
  Agbor et al[@b11-hiv-10-225]                Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Alemie and Gebreselassie[@b18-hiv-10-225]   U    Y    N    U    Y    Y    U    Y    Y    Y     6       2   2
  Amare[@b19-hiv-10-225]                      Y    Y    Y    Y    Y    N    N    Y    Y    Y     8       2   0
  Gebreegziabher et al[@b20-hiv-10-225]       Y    Y    Y    Y    U    Y    Y    Y    Y    Y     9       0   1
  Daniel et al[@b28-hiv-10-225]               Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Deribew et al[@b21-hiv-10-225]              Y    N    Y    Y    Y    Y    Y    Y    Y    Y     9       1   0
  Esmael et al[@b22-hiv-10-225]               Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Feldacker et al[@b45-hiv-10-225]            Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Gupta et al[@b32-hiv-10-225]                Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Hailu et al[@b23-hiv-10-225]                Y    U    Y    Y    Y    Y    Y    Y    Y    Y     9       0   1
  Hoffmann et al[@b33-hiv-10-225]             Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Iliyasu and Babashani[@b31-hiv-10-225]      Y    Y    Y    Y    Y    Y    Y    Y    N    Y     9       1   0
  Kamenju and Said[@b42-hiv-10-225]           Y    Y    N    Y    Y    Y    Y    Y    U    Y     8       1   1
  Malkin et al[@b44-hiv-10-225]               Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Mekonnen et al[@b24-hiv-10-225]             Y    U    U    Y    Y    Y    Y    Y    U    Y     7       0   3
  Muttai et al[@b46-hiv-10-225]               Y    Y    U    Y    Y    Y    Y    Y    Y    Y     9       0   1
  Namme et al[@b36-hiv-10-225]                Y    N    U    Y    Y    Y    Y    Y    Y    Y     8       1   1
  Njozing et al[@b37-hiv-10-225]              Y    Y    Y    Y    Y    N    N    Y    Y    Y     8       2   0
  Ocama et al[@b38-hiv-10-225]                Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Nglazi et al[@b34-hiv-10-225]               Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Siddiqi et al[@b40-hiv-10-225]              Y    Y    U    Y    Y    Y    Y    Y    Y    Y     9       0   1
  Skogmar et al[@b25-hiv-10-225]              Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Tarekegne et al[@b26-hiv-10-225]            Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Wobudeya et al[@b39-hiv-10-225]             Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Yassin et al[@b27-hiv-10-225]               Y    Y    U    Y    Y    Y    Y    Y    Y    Y     9       0   1
  Sinkala et al[@b41-hiv-10-225]              Y    Y    Y    Y    Y    Y    Y    Y    Y    Y     10      0   0
  Stolp et al[@b47-hiv-10-225]                Y    Y    Y    Y    Y    Y    Y    Y    U    Y     9       0   1
  van der Plas et al[@b35-hiv-10-225]         Y    Y    U    Y    Y    Y    Y    Y    Y    Y     9       0   0

**Abbreviations:** EPTB, extrapulmonary tuberculosis; JBI, Joanna Briggs Institute; N, number; PLWHA, people living with HIV/AIDS; Q, question; SSA, sub-Saharan Africa; U, unclear; Y, yes.

###### 

Heterogeneity assessment summary by using sensitivity and subgroup analyses, SSA, 2017

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subgroup analysis (PICO)                               Number of studies   Prevalence of EPTB (95% CI), random-effects model   Heterogeneity         
  ------------------------------------------------------ ------------------- --------------------------------------------------- --------------- ----- ------------
  **Overall**                                            31                  20% (17, 22)                                        0               94    \<0.00001

  **Sensitivity analysis by removing one large study**   30                  20% (17, 23)                                        0.01            94    \<0.00001

  **Clinical heterogeneity by age groups**\              3\                  17% (3, 31)\                                        0.01\           97\   \<0.00001\
  Children \<15 years\                                   7\                  23% (14, 32)\                                       0.01\           97\   \<0.00001\
  Adults \>15 or \>18 years\                             21                  18% (16, 19)                                        0               86    \<0.00001
  All age groups                                                                                                                                       

  **Clinical heterogeneity by EPTB types**\              27\                 22% (19, 25)\                                       0.01\           97\   \<0.00001\
  Different EPTB\                                        2\                  14% (12, 16)\                                       0               0     0.65
  TB of lymph node\                                      2                   One each, not estimated                                                   
  TB of hepatic or TB of abdomen                                                                                                                       

  **Methodological heterogeneity by study design**\      9\                  20% (13, 27)\                                       0.01\           96\   \<0.00001\
  Cross-sectional\                                       14\                 19% (16, 22)\                                       0\              91\   \<0.00001\
  Retrospective record review\                           5\                  23% (17, 29)\                                       0\              97\   \<0.00001\
  Retrospective cohort\                                  2                   16% (11, 20)                                        0               36    0.21
  Prospective cohort                                                                                                                                   

  **By subregion of SSA**\                               16\                 20% (16, 23)\                                       0\              92\   \<0.00001\
  Eastern SSA\                                           4\                  21% (15, 26)\                                       0\              92\   \<0.00001\
  Southern SSA\                                          10\                 19% (13, 24)\                                       0.01            96    \<0.00001
  Western SSA\                                           1                   Not estimated                                                             
  Central SSA                                                                                                                                          

  **By countries of SSA having ≥ two studies**\          10\                 23% (17, 29)\                                       0.01\           93\   \<0.00001\
  Ethiopia\                                              4\                  15% (7, 24)\                                        0.01\           94\   \<0.00001\
  Nigeria\                                               3\                  25% (12, 37)\                                       0.01\           97\   \<0.00001\
  Cameroon\                                              4\                  17% (14, 20)\                                       0\              84\   0.0003\
  South Africa\                                          2\                  12% (7, 17)\                                        0\              35\   0.21\
  Uganda\                                                2\                  15% (12, 18)\                                       0\              0\    0.74\
  Zambia\                                                6                   17% (14, 20)                                        0               84    \<0.0001
  Others                                                                                                                                               

  **Study time variation**\                              1\                  Not estimated\                                      0.02\           94\   \<0.00001\
  1990--2000\                                            3\                  19% (3, 34)\                                        0               94    \<0.00001
  2001--2010\                                            27                  20% (18, 23)                                                              
  2011--2017                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** EPTB, extrapulmonary tuberculosis; PICO, people, intervention, comparison, outcomes; SSA, sub-Saharan Africa; TB, tuberculosis.
